Evidence map›Paper›PMID 32250293›Full record

ReviewJournal of Alzheimer's disease : JAD2020

Is Alzheimer's Disease a Liver Disease of the Brain?

Margaret F Bassendine, Simon D Taylor-Robinson, Michael Fertleman, Michael Khan, Dermot Neely

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 118 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Interactions with polygenic background impact quantitative traits in the UK Biobank.medRxiv : the preprint server for health sciences · 2025
    Article
  14. Article
  15. Article
  16. Plasma proteomic Alzheimer's risk score: Biological age clock and pseudotime trajectory.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  17. Liver, ageing and disease.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  18. Article
  19. ACS chemical biology · 2025
    Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Margaret F BassendineInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Simon D Taylor-RobinsonDepartment of Hepatology & Gastroenterology, Division of Surgery and Cancer, Imperial College London, St Mary's Campus, UK.
Michael FertlemanDepartment of Hepatology & Gastroenterology, Division of Surgery and Cancer, Imperial College London, St Mary's Campus, UK.
Michael KhanUniversity of Warwick & University Hospitals of Coventry and Warwickshire NHS Trust, UK.
Dermot NeelyInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Imperial College London · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBUniversity Hospitals Coventry and Warwickshire NHS Trust · GB

Funding

Department of Health 2011-NIHR 7068
6 · The paper itself

Abstract

Clinical specialization is not only a force for progress, but it has also led to the fragmentation of medical knowledge. The focus of research in the field of Alzheimer's disease (AD) is neurobiology, while hepatologists focus on liver diseases and lipid specialists on atherosclerosis. This article on AD focuses on the role of the liver and lipid homeostasis in the development of AD. Amyloid-β (Aβ) deposits accumulate as plaques in the brain of an AD patient long before cognitive decline is evident. Aβ generation is a normal physiological process; the steady-state level of Aβ in the brain is determined by balance between Aβ production and its clearance. We present evidence suggesting that the liver is the origin of brain Aβ deposits and that it is involved in peripheral clearance of circulating Aβ in the blood. Hence the liver could be targeted to decrease Aβ production or increase peripheral clearance.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainHumansLipid MetabolismLiverMetabolic SyndromeAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAlzheimer’s diseaseapolipoprotein Ecircadianhepatitis C viruslivermetabolic syndromesmall interfering RNAs

Identifiers

PMID32250293
PMCPMC7306895
OpenAlexW3014127696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.